Events

Scientific Conferences and Shows

HUPO lX World Congress,
Sun, 2010-09-19 - Thu, 2010-09-23
Sydney, Australia

Booth at HUPO -
Bio-Rad – Hall A, Booth 1

WorkShops and Seminars

Bio-Rad will be hosting a Proteomics Workshop Luncheon on Monday, Sept 20, 2010. The workshop includes a seminar given by Dr. Stefan Lehr from the German Diabetes Center, Dusseldorf, Germany on high-throughput protein profiling and high-confidence identification for biomarker discover using the Lucid Proteomics System™

Posters

Poster Session 1: Monday (9/20), 15:00–16:30, Abstract Number 407
Phosphoprotein Profiling: Combining Hydroxyapatite-based Phosphoprotein Enrichment with Retentate Chromatography MALDI-TOF Mass Spectrometry using the Lucid Proteomics System

Poster Session 2: Tuesday (9/21), 15:00–16:30, Abstract Number 397
Analysis of Alzheimer’s Disease Samples using Antibody and Chromatographic Arrays Combined with MALDI-TOF Mass Spectrometry using the Lucid Proteomics System

Poster Session 2: Tuesday (9/21), 15:00–16:30, Abstract Number 411
Clinical Sample Proteomic Profiling: Time-course Reproducibility of Retentate Chromatography MALDI-TOF Mass Spectrometry using the Lucid Proteomics System

Poster Session 3: Wednesday (8/22), 15:00 – 16:30, Abstract Number 789
Support Vector Machine in Lucid Proteomics Software Increases the Predictive Power of Biomarkers

Case Studies

Vermillion Uses Bio-Rad’s SELDI Technology to Develop the OVA1 Ovarian Cancer Test

Snapshot

In September 2009, the U.S. Food and Drug Administration cleared Vermillion’s OVA1 test as an aid in distinguishing between benign and malignant ovarian tumors. Bio-Rad’s SELDI platform was instrumental in helping Vermillion discover and validate the OVA1...

[More...]

Press Coverage

2009-12-11: (ProteoMonitor) The Biomarkers That Could: How Five Biomarkers Might Be the Key to Vermillion's turnaround

By becoming the first proteomics IVDMIA to gain FDA clearance, Vermillion’s OVA1 ovarian cancer test might be the key to Vermillion’s success. SELDI, a key component in the Lucid Proteomics System, is the technology that powered the development and validation of the test.

[More...]

2009-12-07: (Drug Discovery and Development) Bottom-Up or Top-Down?

A review of methodologies for biomarker discovery and identification, including the Lucid Proteomics System.

[More...]

2009-08-08: (sp2 Magazine) A New Combined Approach in Biomarker Discovery

Researchers can use the Lucid Proteomics System to access the full range of proteins that may lead to clinically relevant biomarkers.

[More...]

2009-06-05: (ProteoMonitor) New Technology Combining Bruker's MALDI-TOF/TOF with Bio-Rad's SELDI Set to Launch

Bruker and Bio-Rad Laboratories launch the Lucid Proteomics System, which links Bruker's MALDI-TOF/TOF platform with Bio-Rad's SELDI technology to enable researchers to detect a class of proteins and peptides that other technologies have tripped over.

[More...]

Press Releases

The latest news about the Lucid Proteomics System.

Lucid Proteomics System from Bio-Rad and Bruker Combines Top-Down and Bottom-Up Proteomics to Improve Biomarker Discovery

Bio-Rad and Bruker officially announce the launch of the Lucid Proteomics System, the first system to combine top-down and bottom-up proteomics approaches for biomarker discovery.

FDA Approves Vermillion's Ovarian Cancer Test; Launch Slated for Q4

The FDA approval of an ovarian cancer test, called OVA1, is based on biomarkers discovered and validated using the SELDI platform. OVA1 is an in vitro diagnostic multivariate index assay, and the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity before a biopsy or exploratory surgery. It can also diagnose cancer even in instances where radiological tests fail to indicate malignancy.

Bio-Rad Introduces the LUCID ID Access Pack to Complete Top-Down Biomarker Discovery Workflow

Bio-Rad and Bruker announce the launch of the first product of the Lucid Proteomics System. Researchers who currently profile their biomarkers using BioRad’s ProteinChip® array technology can use the Lucid ID Access Pack to complete the biomarker purification process and identify these biomarkers with high confidence.

Bio-Rad and Bruker Partner to Offer New Solutions for Biomarker Discovery and Development

Bio-Rad and Bruker Sign Joint Product Development and Co-Marketing Agreement